test

Barbara Burtness MD

Clinical Research Program Leader, Head and Neck Cancers Program; Co-Director, Developmental Therapeutics Research Program; Professor of Medicine (Medical Oncology)

Research Interests

EGFR expressed head and neck cancers.


Research Summary

Studies of targeted treatments for EGFR expressed head and neck cancers. She has shown that high EGFR expression predicted resistance to cetuximab in head and neck cancers and is the principal investigator of a phase I clinical trial of cetuximab with escalating doses of the mTOR inhibitor everolimus to target signaling from pAkt, and an investigator-initiated phase II trial of chemotherapy plus cetuximab, followed by addition of erlotinib.

Extensive Research Description

Studies of targeted treatments for EGFR expressed head and neck cancers. She has shown that high EGFR expression predicted resistance to cetuximab in head and neck cancers and is the principal investigator of a phase I clinical trial of cetuximab with escalating doses of the mTOR inhibitor everolimus to target signaling from pAkt, and an investigator-initiated phase II trial of chemotherapy plus cetuximab, followed by addition of erlotinib.


Selected Publications

  • Burtness B. Targeted agents: management of dermatologic toxicities. J Natl Compr Canc Netw. 2014 May;12(5 Suppl):793-6.PMID: 24853219
  • Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol. 2013 Jul;14(8):e302-9. doi: 10.1016/S1470-2045(13)70085-8. Review. PMID: 23816296
  • Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova AS, Golemis EA, Flieder DB, Cooper HS, Lango M, Ridge JA, Burtness B. Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. Clin Cancer Res. 2013 Dec 1;19(23):6633-43. doi: 10.1158/1078-0432.CCR-13-0152. Epub 2013 Oct 2. PMID: 24088734
  • Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol. 2014 Mar 28. [Epub ahead of print] PMID: 24685886
  • Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res. 2014 Jun 1;20(11):3023-32. doi: 10.1158/1078-0432.CCR-14-0113. Epub 2014 Apr 3. PMID: 24700741
  • Argiris A, Li S, Ghebremichael M, Egloff AM, Wang L, Forastiere AA, Burtness B, Mehra R. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Ann Oncol. 2014 Jul;25(7):1410-6. doi: 10.1093/annonc/mdu167. Epub 2014 May 5. PMID: 24799460

Edit Profile